PR status

What it is

PR status is the progesterone receptor test result in breast cancer, usually reported as positive or negative on tumour cells, and current pathology guidance commonly treats 1% or more tumour-cell staining on immunohistochemistry as receptor-positive. PR testing is done on a biopsy or surgery specimen, usually alongside estrogen receptor (ER) and HER2 testing, because these markers help classify the cancer and guide treatment. In practice, a PR-positive result often means the tumour is part of the broader hormone receptor-positive group, especially when ER is also positive. PR status is not interpreted alone. Doctors read it together with ER status, HER2 status, tumour grade, stage, menopausal status, and sometimes genomic tests.

In breast cancer, progesterone receptors are proteins inside cells that can reflect an active estrogen-signaling pathway. Because of that, PR positivity often supports the idea that endocrine therapy such as tamoxifen or an aromatase inhibitor may help, although ER status is generally the stronger and more established predictor of endocrine sensitivity.

A simple way to read common reports is:

PR result	What it usually means
PR positive	Tumour cells show progesterone receptor expression; often seen with ER-positive disease
PR negative	No meaningful progesterone receptor expression detected
Low positive	Small proportion of cells stain positive; significance can be less clear than strong positivity

How it works

PR testing is usually performed by immunohistochemistry (IHC) in a pathology laboratory. A pathologist applies antibodies to the tumour sample to see whether cancer-cell nuclei stain for progesterone receptor. The report may include:

1. Positive or negative result
2. Percentage of tumour cells staining
3. Staining intensity in some labs
4. Composite score such as an Allred score in some reports

Biologically, PR is a steroid hormone receptor regulated in part by estrogen signaling. That is why PR expression often travels with ER positivity. In many breast cancers, an ER-positive/PR-positive pattern suggests a more clearly hormone-driven tumour biology than ER-positive/PR-negative disease. By contrast, a reported ER-negative/PR-positive pattern is uncommon and has raised concern in the literature because it may reflect technical or interpretive issues rather than a stable, reproducible subtype.

Pre-analytic factors matter. Delays in fixing the tissue, poor fixation, small samples, and laboratory variability can affect receptor staining. This is one reason repeat testing may be considered if the result seems unexpected or does not fit the clinical picture.

Evidence and uses

The main use of PR status is to help guide treatment decisions in breast cancer. It is not a screening test for healthy people and it is not a blood test. It is a tumour biomarker used after cancer is diagnosed.

PR status helps in these ways:

• Classifying the tumour as hormone receptor-positive or not, together with ER
• Estimating prognosis in context, since PR-positive tumours often have somewhat more favorable biology than PR-negative tumours within ER-positive disease
• Supporting endocrine therapy decisions, especially when interpreted with ER status
• Helping explain treatment response patterns in some patients

Most hormone receptor-positive breast cancers are ER positive, and many are also PR positive. Mayo Clinic notes that most ER-positive breast cancers are also PR positive. In routine care, ER status remains the key predictive marker for endocrine therapy, while PR adds useful but secondary information.

Examples of common combinations include:

ER/PR pattern	Typical interpretation
ER positive / PR positive	Classic hormone receptor-positive disease; endocrine therapy often important
ER positive / PR negative	Still hormone receptor-positive, but may behave somewhat more aggressively or be less endocrine-sensitive than ER+/PR+ disease
ER negative / PR positive	Uncommon; may warrant review or repeat testing because reproducibility is limited
ER negative / PR negative	Hormone receptor-negative disease

Research suggests PR loss in ER-positive breast cancer can be associated with higher-grade disease and worse outcomes than ER-positive/PR-positive disease. Meta-analytic and review data support PR as a prognostic marker, but its exact independent value varies across studies and treatment settings. Modern treatment decisions also rely on stage, nodal status, HER2, Ki-67 in some settings, and multigene assays where available.

In India, PR testing is part of standard breast cancer pathology work-up in oncology centres, usually with ER and HER2, because these results affect whether endocrine therapy is likely to be offered. Access and reporting detail can vary by laboratory, so patients may see either a simple positive/negative result or a more detailed pathology score.

Diagnosis / how it's measured

PR status is measured on tumour tissue, not from symptoms alone. The sample usually comes from:

• Core needle biopsy
• Lumpectomy specimen
• Mastectomy specimen
• Occasionally a metastatic site biopsy if the cancer returns or spreads

The pathology report may state PR in one of several formats:

1. Positive/negative
2. Percent positive nuclei, such as 0%, 5%, or 80%
3. Allred score, which combines proportion and intensity

According to major pathology guidance used internationally, breast cancers with 1% to 100% of tumour nuclei positive for ER or PR are interpreted as positive by IHC. Still, not all positive results carry the same clinical weight. A tumour with very low receptor expression may behave differently from one with strong, diffuse staining.

If the result is surprising, clinicians may ask questions such as:

• Was the tissue fixed promptly and properly?
• Is there enough invasive tumour in the sample?
• Should the test be repeated on another block or specimen?
• If the cancer recurs, should receptors be retested on the new site?

Retesting can matter because receptor status can occasionally differ between the original tumour and a recurrence or metastasis.

When to see a clinician

See your cancer specialist or breast surgeon if you have a pathology report showing PR status and you do not understand how it affects treatment. Ask specifically how your ER, PR, and HER2 results fit together, because PR alone rarely answers the treatment question.

You should also ask for clarification if your report says ER-negative/PR-positive, low positive, or if different labs gave different receptor results. These patterns may need pathology review. If breast cancer comes back after earlier treatment, ask whether a new biopsy and repeat receptor testing are needed.

Limitations and open questions

PR status is useful, but it has limits. It is not a stand-alone predictor of outcome or treatment benefit. ER status is generally more central for endocrine therapy decisions, and PR mainly adds context.

Evidence also shows that some unusual receptor patterns are not highly reproducible. In particular, ER-negative/PR-positive breast cancer appears uncommon and may partly reflect technical artifacts or interpretation problems. That means clinicians should be cautious about making major decisions from an unexpected PR result without reviewing the pathology.

Another limitation is that laboratory methods are not perfectly uniform across all settings. Fixation time, antibody selection, scoring system, and pathologist interpretation can influence the result. Low-level positivity is an area where uncertainty remains, especially when trying to predict exactly how much benefit endocrine therapy will provide.

PR biology itself is also more complex than a simple positive/negative label. Research continues on progesterone receptor isoforms, cross-talk with ER and growth-factor pathways, and whether PR can better refine prognosis or treatment selection in specific subgroups. For now, PR status remains an important but supporting biomarker within the larger breast cancer profile.